OctoPlus wins new drug delivery evaluation contract

Published: 17-Nov-2008

Dutch biopharmaceutical company OctoPlus has signed a new drug delivery technology evaluation contract with an unnamed US-based biotech company.


Dutch biopharmaceutical company OctoPlus has signed a new drug delivery technology evaluation contract with an unnamed US-based biotech company.

In October, as part of its strategic focus on developing controlled release formulations for clients, OctoPlus signed an agreement with Biolex Therapeutics to license Locteron, a product based on OctoPlus' PolyActive drug delivery technology, to Biolex.

Locteron is a controlled release formulation of interferon alfa for the treatment of chronic hepatitis C, which has been licensed to Biolex Therapeutics and is being manufactured by OctoPlus. Locteron is currently in Phase II clinical studies.

OctoPlus' strategy will increasingly focus on developing controlled release versions of existing or new drugs for clients, in addition to providing general formulation development and clinical material manufacturing. Currently, OctoPlus is working on five projects to develop a controlled release formulation for a client.

Under this latest contract, OctoPlus will evaluate the feasibility of a controlled release formulation that combines the active ingredient of the client with OctoPlus' proprietary drug delivery technology. If the evaluation is successful, the contract may progress to a full process development, manufacturing and licensing agreement.

You may also like